Pattern hair loss

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Charles River to Perform Plasmid Production for Ship of Theseus

Retrieved on: 
Thursday, April 4, 2024
Health, Medical Devices, Stem Cells, Genetics, General Health, Pharmaceutical, Biotechnology, Diabetes, Neutropenia, CDMO, Psoriasis, Infertility, Cancer, MCB, Tissue, CRL, DNA, Research, Pattern hair loss, HOX, Ship, Acquisition, Factorization of polynomials, Display resolution, GMP, Good manufacturing practice, Tecmar, Therapy, HQ, Vaccine

Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement.
  • Ship of Theseus will leverage Charles River’s premier expertise to manufacture GMP plasmid DNA to serve as the active drug substance for its lead candidate.
  • Charles River’s GMP plasmid DNA CDMO center of excellence based in Keele, United Kingdom will lead the collaboration, providing services that include plasmid DNA backbone generation, plasmid synthesis, GMP master cell bank (MCB) generation, pre-production evaluation, and GMP plasmid DNA manufacture including in-house release testing.
  • We trust the team’s decades of success developing, producing, and reliably delivering plasmid DNA and look forward to bringing our therapies to patients.” – Jeremy Elser, Founding CEO, Ship of Theseus

Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study

Retrieved on: 
Saturday, March 9, 2024
MPC, Woman, LDH, CMO, LOS, Hair loss, Blood, Pattern hair loss, Biopsy, Fur, Skin, Data, Annual general meeting, B cell, AAD, Patient, Clinical trial, Inhibitor, American Academy, Pharmaceutical industry

LOS ANGELES, March 9, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, today presented positive translational and Phase 1 clinical data demonstrating the company's novel small molecule therapy PP405 reactivates dormant hair follicle stem cells to trigger hair growth. Data were presented in a late-breaking oral session of the American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego, titled Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo.

Key Points: 
  • Data were presented in a late-breaking oral session of the American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego, titled Inhibition of pyruvate oxidation activates human hair follicle stem cells ex vivo.
  • "The translational data derived from our ex vivo studies on human facelift skin have been further validated in a Phase 1 first-in-human clinical trial demonstrating PP405 effectively reactivates dormant hair follicle stem cells," said Daniel Gil, Ph.D., CEO of Pelage Pharmaceuticals.
  • The LDH activity corresponded with a significant increase in Ki67 signal in the hair bulge, indicating a proliferative response of the hair follicle stem cells.
  • PP405 may also have applications for other forms of alopecia, including telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.

Latest Updates of Viva Biotech's Portfolio Companies

Retrieved on: 
Wednesday, March 6, 2024
Fabry disease, RMB, PD, Drug development, Strong, Ohio State University, RNA, Insight Partners, Pharmacology, American College, Radiopharmaceutical, VBI, Willebrand, RTW, Pattern hair loss, GMP, Stroke, Good manufacturing practice, Therapy, Skin, GCS, Atopic dermatitis, Safety, Pharmacokinetics, Von Willebrand factor, Investment, AstraZeneca, Innovation, Groundbreaking, Patient, ARCH Venture Partners, Pharmaceutical industry

NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs). Recently they announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy. AL01211 is a potent, oral, glucosylceramide synthase (GCS) inhibitor being developed for the treatment of Fabry disease and Type 1 Gaucher disease.

Key Points: 
  • This continuous innovation keeps companies up to date and promotes the evolution of R&D and the success of commercialization.
  • Recently, Viva Biotech's portfolio companies have new updates.
  • NEWARK, Calif.-- AceLink Therapeutics, Inc., invested and incubated by Viva BioInnovator (VBI), is a clinical-stage biopharmaceutical company developing next generation oral substrate reduction therapies (SRTs).
  • Previously, the company had completed a $5.4 million seed funding round, with investors including Rev1 Ventures, Broadview Ventures, and Viva Biotech.

Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine for Hair Loss

Retrieved on: 
Tuesday, February 27, 2024
MPC, Woman, CMO, LOS, Hair loss, GV, Pattern hair loss, Hospital, Fur, Harvard University, Faculty, University, YK, Massachusetts General Hospital, Harvard Medical School, DRS, American Academy, Pharmaceutical industry

LOS ANGELES , Feb. 27, 2024 /PRNewswire/ -- Pelage Pharmaceuticals, a clinical-stage regenerative medicine company pioneering a new generation of treatments for hair loss, announced today that the company has closed a $16.75 million Series A financing led by GV with participation from Main Street Advisors, Visionary Ventures and YK BioVentures, to advance a first-in-class treatment for androgenetic alopecia or pattern baldness, and other types of alopecia including chemotherapy-induced hair loss.

Key Points: 
  • Additionally, PP405 may also have applications for other types of hair loss such as telogen effluvium (stress-induced hair loss) and chemotherapy-induced hair loss.
  • "What we've observed is that in people who experience hair loss, the actual hair follicle stem cells are still present but have reverted to a dormant state.
  • "Hair loss is an incredibly common health problem with few effective solutions," said Cathy Friedman, Executive Venture Partner, GV and Board Director, Pelage Pharmaceuticals.
  • Pelage is built on rigorous science and offers the opportunity to target the follicle stem cells directly," said Dr. Weng.

Zylö’s ‘Powered by Z-pods®’ technology incorporated into BosleyMD’s new product line

Retrieved on: 
Tuesday, February 6, 2024
Foam, Intelligence, Cable television, Male, CVS, Walmart, Hair loss, Y100, Pattern hair loss, Skin, Mouse, Ulta Beauty, Female, Sale, Nature, Advertising

GREENVILLE, SC, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Zylö’s Z-pod® topical delivery platform is being used by BosleyMD—the Thinning Hair Authority™—as a key feature in their newly launched product line, Revive+ Densifying Foam. BosleyMD is currently offering a male version and a female version through CVS and online (see link below); distribution through Walmart and Ulta Beauty is expected soon. Cable TV and online advertising will be used to promote the products.

Key Points: 
  • As explained on the back of the Revive+ package, Zylö’s technology provides SUPERIOR SUSTAINED DELIVERY, with the tagline: Encapsulated for precise delivery to the follicles and sustained release up to 24 hours.
  • The Z-pods also provide enhanced delivery to hair follicles, perfect for a hair-growth product.
  • With the Revive+ product line, the Z-pods encapsulate the active ingredient Y100, a natural ingredient that is extracted and purified from the alma tree.
  • Scott Pancoast CEO + founder of Zylö, stated, "Congratulations to YuvaBio and BosleyMD for the successful launch of the Revive+ product line.

Stemson Therapeutics Announces Technological Breakthrough in New Hair Growth

Retrieved on: 
Tuesday, February 6, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical Trials, Other Health, Multimedia, Anxiety, GFP, Cell, Machine learning, Hair loss, Patient, Transplant, Big data, EFU, Skin, Mouse, Depression, Therapy, Quality of life, Pattern hair loss, Medicine, Algorithm, Doctor of Philosophy, Data science, Wool

Stemson Therapeutics today announced a major technological advance that clears the path for its proprietary hair rejuvenation solution to advance toward human clinical trials.

Key Points: 
  • Stemson Therapeutics today announced a major technological advance that clears the path for its proprietary hair rejuvenation solution to advance toward human clinical trials.
  • Stemson is developing an iPSC-derived autologous cell therapy to regenerate healthy hair follicles and has successfully created human hair follicles in humanized mice using engineered follicular units.
  • C. Enlarged image of hair bulb demonstrating green fluorescent protein (GFP) labelled cells from Stemson EFUs are responsible for generating human hair follicles in skin pad.
  • “Stemson is poised to deliver truly novel and effective hair growth treatments to hair loss patients.

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Retrieved on: 
Tuesday, December 5, 2023
Sun Pharma, Alopecia areata, Therapy, Patent, Sun, Pattern hair loss, ACRS, AA, Generic drug

WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma).

Key Points: 
  • WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, today announced an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma).
  • Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA).
  • Aclaris exclusively licenses the patents from a third party, and has separate contractual obligations under which it owes a portion of the consideration received from Sun Pharma.
  • “We are pleased to announce this patent license agreement with Sun Pharma, which represents our second out-license for this patent portfolio,” stated James Loerop, Chief Business Officer of Aclaris.

Veradermics Co-Founder and CEO, Reid Waldman, Named to the 2023 Forbes "30 Under 30" Healthcare List

Retrieved on: 
Wednesday, November 29, 2023
Entrepreneurship, Wart, Clinical trial, Medicine, American Academy, Cedars-Sinai Medical Center, University, Pattern hair loss, Atopic dermatitis, Therapy, American Academy of Dermatology, Health care, Health, Skin, Physician, Publication, Hair loss, Molluscum contagiosum, Pharmaceutical industry, Dermatology

NEW HAVEN, Conn., Nov. 29, 2023 /PRNewswire-PRWeb/ -- Veradermics Inc., a clinical-stage medical dermatology company developing new therapeutics for a range of skin and hair loss conditions, today announced that Co-Founder and CEO, Reid Waldman, has been included in the 2023 Forbes "30 Under 30" Healthcare list, recognizing leading scientists and entrepreneurs developing innovative solutions that address some of healthcare's biggest challenges.

Key Points: 
  • Two products of which Waldman is an inventor, including an immune stimulatory microarray for warts and a non-hormonal oral therapeutic for androgenetic alopecia, are currently in clinical trials.
  • In a significant milestone, the company recently announced the dosing of the first patient in a clinical trial for its non-hormonal oral therapeutic for pattern hair loss.
  • In addition to the two therapeutics currently in trials for warts and pattern hair loss, Veradermics pipeline also includes candidates targeting alopecia areata, atopic dermatitis, and molluscum contagiosum.
  • The company expects to advance these additional product candidates into the clinic in 2024.

Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia

Retrieved on: 
Thursday, October 26, 2023
Female, Pattern hair loss, Technology transfer, AGA, III, CMC, CDMO, EM, Hair, Biopharmaceutical, Patient, Mab, Endometriosis, BLA, Vaccine, Pharmaceutical industry

Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115.

Key Points: 
  • Chime Biologics to support the late-stage clinical study and to provide global commercial manufacturing services for Hope Medicine's first-in-class monoclonal antibody drug, HMI-115.
  • Hope Medicine will leverage Chime Biologics' extensive experience in 2000L cGMP manufacturing, late-stage CMC development and BLA filings to jointly accelerate HMI-115 mAb development and manufacturing for speedy clinical advancement of targeting endometriosis and androgenetic alopecia, benefiting more female patients and alopecia patients.
  • Dr. Damian Tu, President of Hope Medicine, said, "HMI-115 is Hope Medicine's most critical and advanced clinical antibody drug asset.
  • Dr. Jimmy Wei, President of Chime Biologics, said, "We are pleased to be a strategic partner of Hope Medicine.